$1.50
CURRENT ($)
-0.08
24-hour Change ($)
-5.06%
24-hour Change (%)
LOCAL ADVANTAGE
GLOBAL OPPORTUNITY
As one of the largest players in the supply chain, Valens is a premium cannabis producer and processor with exciting international growth potential. This is your opportunity to get on board with a truly diversified cannabis company poised to generate continuous, long-term return.
We’ve planted our roots
and we’re here to stay.
Current market.
$1.50
CURRENT ($)
CURRENT ($)
-0.08
24-hour Change ($)
24-hour Change ($)
-5.06%
24-hour Change (%)
24-hour Change (%)
The world is our market.
With the ability to import and export internationally, Valens is set up for every servicing and consumer product opportunity, globally.
Multi-licensed
- Health Canada Dealer’s License (multiple)
- Health Canada ACMPR Cultivation and Processing License
- ISO 17025 Lab accredited – First in Canada for Cannabis
- Thermo Fisher Scientific “Centre of Excellence for Plant-Based Science”
- EU GMP Certification pending
Our Subsidiaries
Valens AgriTech
Premium, proprietary extraction services, and R&D
Valens Labs
Globally-recognized testing and analysis
Valens Farms
State-of-the-art, single strain growing capabilities
Industry Support
Valens has received validation from an $80B company, Thermo Fisher Scientific. We’re also the preferred partner of Canopy Growth and other industry leaders.
Investor Presentations
Public Filings
Exceptional Partners.
We work with a number of renowned partners who share our commitment to innovation and supreme quality.
The numbers.
7,000
Medical Patients Registered in Canada by 2020
Medical Patients Registered in Canada by 2020
$1.2B
Canadian Medical Market Size
Canadian Medical Market Size
$4.3B
Potential Candian Recreational sales in 2019
Potential Candian Recreational sales in 2019
€115.7B
European medical and recreational markets expected growth by 2028
European medical and recreational markets expected growth by 2028
The Bottom Line:
With the global legal marijuana market expected to reach 146.4 billion USD by 2025, Valens is in a rare position to capitalize on international opportunities.
The Valens Advantage.
- Full control and transparency from seed to final sale
- Proprietary methods for extraction
- Research and analysis grants
- International capabilities
- Diverse product range
What’s next?
Valens has already made significant strides. By the end of 2018, we will:
- Receive pending GMP certification
- Begin sales of recreational cannabis products and services to Canadian LP’s
- Commence medical sales to international markets
- Launch the Valens brand
Stay up to date.
Sign up to receive the latest investor information and company news.
Scott Young with Investor Relations
at 705-888-2756 or scott@valensgroworks.com.